<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069376</url>
  </required_header>
  <id_info>
    <org_study_id>N201802031</org_study_id>
    <nct_id>NCT05069376</nct_id>
  </id_info>
  <brief_title>Effect of Ureteral Stents Length and Location on Related Symptom</brief_title>
  <official_title>Effect of Ureteral Stents Length and Location on Related Symptom</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University Shuang Ho Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University Shuang Ho Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized clinical trial, evaluating the effect of the intra-ureteral&#xD;
      placement of the stent's distal end versus the conventional stent placement on the&#xD;
      postoperative LUTS and pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravesical stent mass has been considered to cause stent-related symptoms, such as LUTS and&#xD;
      pain. The current study hypothesized that the total intra-ureteral placement of the stent's&#xD;
      distal end could decrease postoperative LUTS and pain. We proposed a prospective randomized&#xD;
      trials, investigating the effect of intra-ureteral stent placement versus conventional stent&#xD;
      placement. The primary end point was postoperative LUTS. The secondary end points were&#xD;
      postoperative pain and quality of life. We used USSQ questionnaire as the assessing tool.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Actual">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1: Intra-ureteral placement of double-J stent Arm 2: Conventional placement of double-J stent</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients were not informed the allocation until the stent was removed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Lower urinary tract symptom after placement of D-J stent</measure>
    <time_frame>Before removal of D-J stent</time_frame>
    <description>The symptoms are evaluated by a complete USSQ (Ureteral Stent Symptom Questionnaire) urinary index. The minimum and maximum values are 11 and 53, and the higher scores mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain after placement of D-J stent</measure>
    <time_frame>Before removal of D-J stent</time_frame>
    <description>The symptoms are evaluated by a complete USSQ (Ureteral Stent Symptom Questionnaire) pain index and general health index. The minimum and maximum values of the body pain index are 2 and 43. The minimum and maximum values of the general health index are 4 and 28. The higher scores of both mean a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Lower Urinary Tract Symptoms</condition>
  <condition>Overactive Bladder Syndrome</condition>
  <arm_group>
    <arm_group_label>The intraureteral placement of distal end of ureteral stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this group received 5-16/5-18 D-J stent with intraureteral placement of the distal end</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The conventional placement of the distal end of ureteral stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group received 5-22/5-24 D-J stent with bladder placement of the distal end</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ureteral Stent of 5-16 or 5-18</intervention_name>
    <description>Boston Scientific Polaris™ Ultra Ureteral Stent</description>
    <arm_group_label>The intraureteral placement of distal end of ureteral stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ureteral Stent of 5-22 or 5-24</intervention_name>
    <description>Boston Scientific Polaris™ Ultra Ureteral Stent</description>
    <arm_group_label>The conventional placement of the distal end of ureteral stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of unilateral ureteral stone&#xD;
&#xD;
          -  Plan to undergo unilateral URS lithotripsy&#xD;
&#xD;
          -  Adult patients (&gt;18 years old)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-stented cases&#xD;
&#xD;
          -  Distal ureteral stones&#xD;
&#xD;
          -  Preoperative urinary tract infection&#xD;
&#xD;
          -  With medications known to influence stent-related symptoms, including alpha-blockers,&#xD;
             antimuscarinics, beta3-agonist&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Other procedures required during the procedure of lithotripsy&#xD;
&#xD;
          -  A stent was expected to be indwelled for more than 10 days (ureteral stricture,&#xD;
             ureteral tumors/polyps, ureteral trauma, and a large amount of stone fragments)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-Hsun Ho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shuang Ho Hospital Taipei Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shuang Ho Hospital Taipei Medical University</name>
      <address>
        <city>New Taipei City</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Medical University Shuang Ho Hospital</investigator_affiliation>
    <investigator_full_name>Chen-Hsun Ho</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Ureteral stent</keyword>
  <keyword>OAB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

